{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:12:42Z","timestamp":1778875962779,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["TJ2021-0111"],"award-info":[{"award-number":["TJ2021-0111"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["PR2020-0171"],"award-info":[{"award-number":["PR2020-0171"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["PR2022-0099"],"award-info":[{"award-number":["PR2022-0099"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling Persson Family Foundation","doi-asserted-by":"publisher","award":["2020-0037"],"award-info":[{"award-number":["2020-0037"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling Persson Family Foundation","doi-asserted-by":"publisher","award":["2023-0113"],"award-info":[{"award-number":["2023-0113"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-02371"],"award-info":[{"award-number":["2020-02371"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-04707"],"award-info":[{"award-number":["2020-04707"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ebiom.2024.105368","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T18:11:06Z","timestamp":1728065466000},"page":"105368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-9079","authenticated-orcid":false,"given":"Xiaonan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-4357","authenticated-orcid":false,"given":"Natallia","family":"Rameika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Rendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margus","family":"Veanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehangshu","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-1869","authenticated-orcid":false,"given":"Sandro","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Al Azhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3577-9822","authenticated-orcid":false,"given":"Ioanna","family":"Tsiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-4851","authenticated-orcid":false,"given":"Pauline","family":"Seeburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahed","family":"Al Nassralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Ljungstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivaylo","family":"Stoimenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-7395","authenticated-orcid":false,"given":"Per","family":"Artursson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus H.","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4526-5788","authenticated-orcid":false,"given":"Daniel","family":"Globisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4140","authenticated-orcid":false,"given":"Tobias","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"634","key":"10.1016\/j.ebiom.2024.105368_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm0306","article-title":"A\u00a0carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in\u00a0vitro and in\u00a0vivo","volume":"14","author":"Sandberg","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41467-020-16399-y","article-title":"Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities","volume":"11","author":"Nichols","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/s41467-020-15111-4","article-title":"Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy","volume":"11","author":"Rendo","year":"2020","journal-title":"Nat Commun"},{"issue":"7015","key":"10.1016\/j.ebiom.2024.105368_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105368_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-12-1894","article-title":"DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy","volume":"19","author":"Yeh","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ebiom.2024.105368_bib6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4155\/fmc.11.121","article-title":"Inhibition of Ras for cancer treatment: the search continues","volume":"3","author":"Baines","year":"2011","journal-title":"Future Med Chem"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105368_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"7411","key":"10.1016\/j.ebiom.2024.105368_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature11331","article-title":"Passenger deletions generate therapeutic vulnerabilities in cancer","volume":"488","author":"Muller","year":"2012","journal-title":"Nature"},{"issue":"7639","key":"10.1016\/j.ebiom.2024.105368_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature21052","article-title":"Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer","volume":"542","author":"Dey","year":"2017","journal-title":"Nature"},{"issue":"6278","key":"10.1016\/j.ebiom.2024.105368_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105368_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2024.105368_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23268","article-title":"Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability","volume":"6","author":"Paolella","year":"2017","journal-title":"Elife"},{"issue":"13","key":"10.1016\/j.ebiom.2024.105368_bib14","first-page":"2765","article-title":"Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms","volume":"57","author":"Mertens","year":"1997","journal-title":"Cancer Res"},{"issue":"R2","key":"10.1016\/j.ebiom.2024.105368_bib13","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1093\/hmg\/ddq365","article-title":"Loss-of-function variants in the genomes of healthy humans","volume":"19","author":"MacArthur","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"7809","key":"10.1016\/j.ebiom.2024.105368_bib15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105368_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A\u00a0program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"issue":"Database issue","key":"10.1016\/j.ebiom.2024.105368_bib17","doi-asserted-by":"crossref","first-page":"D501","DOI":"10.1093\/nar\/gki025","article-title":"NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins","volume":"33","author":"Pruitt","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2024.105368_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115184","article-title":"Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity","volume":"203","author":"Zhang","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ebiom.2024.105368_bib60","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/ncomms4295","article-title":"Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments","volume":"5","author":"Zhang","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105368_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid models of human liver cancers derived from tumor needle biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105368_bib20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bcp.14247","article-title":"CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis","volume":"86","author":"Meloche","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"7319","key":"10.1016\/j.ebiom.2024.105368_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A\u00a0map of human genome variation from population-scale sequencing","volume":"467","author":"Genomes Project","year":"2010","journal-title":"Nature"},{"issue":"6070","key":"10.1016\/j.ebiom.2024.105368_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1215040","article-title":"A\u00a0systematic survey of loss-of-function variants in human protein-coding genes","volume":"335","author":"MacArthur","year":"2012","journal-title":"Science"},{"issue":"7258","key":"10.1016\/j.ebiom.2024.105368_bib23","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nature08211","article-title":"A\u00a0highly annotated whole-genome sequence of a Korean individual","volume":"460","author":"Kim","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105368_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm860","article-title":"Human susceptibility and resistance to Norwalk virus infection","volume":"9","author":"Lindesmith","year":"2003","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105368_bib25","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/diabetes.54.5.1588","article-title":"OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes","volume":"54","author":"Field","year":"2005","journal-title":"Diabetes"},{"issue":"6295","key":"10.1016\/j.ebiom.2024.105368_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/347773a0","article-title":"Identification of the primary gene defect at the cytochrome P450 CYP2D locus","volume":"347","author":"Gough","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ejhg.2009.136","article-title":"Depletion of potential A2M risk haplotype for Alzheimer's disease in long-lived individuals","volume":"18","author":"Flachsbart","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105368_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03602530903118729","article-title":"New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme","volume":"41","author":"Wang","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105368_bib29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hep.1840170508","article-title":"Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma","volume":"17","author":"Takahashi","year":"1993","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105368_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/labinvest.3700223","article-title":"Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas","volume":"85","author":"Nakamura","year":"2005","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105368_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/labinvest.3700218","article-title":"Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases","volume":"85","author":"Lasota","year":"2005","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105368_bib32","first-page":"994","article-title":"The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site","volume":"47","author":"Hanioka","year":"1990","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105368_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199606000-00001","article-title":"Nomenclature for human CYP2D6 alleles","volume":"6","author":"Daly","year":"1996","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105368_bib34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/clpt.1993.44","article-title":"Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6","volume":"53","author":"Wang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105368_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002280050170","article-title":"Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs","volume":"51","author":"Masimirembwa","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovic","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ebiom.2024.105368_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","article-title":"Molecular mechanisms of genetic polymorphisms of drug metabolism","volume":"37","author":"Meyer","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1612","key":"10.1016\/j.ebiom.2024.105368_bib38","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2012.0431","article-title":"Human cytochromes P450 in health and disease","volume":"368","author":"Nebert","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105368_bib39","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.109.028654","article-title":"Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs","volume":"37","author":"Ahlin","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105368_bib40","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1021\/mp400202d","article-title":"An integrated in\u00a0vitro model for simultaneous assessment of drug uptake, metabolism, and efflux","volume":"10","author":"Neve","year":"2013","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105368_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2013.01.010","article-title":"NADPH P450 oxidoreductase: structure, function, and pathology of diseases","volume":"138","author":"Pandey","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105368_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/or.2021.8231","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors (Review)","volume":"47","author":"Zhao","year":"2022","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.ebiom.2024.105368_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A\u00a0global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ebiom.2024.105368_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12935-018-0538-7","article-title":"Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight","volume":"18","author":"Lohitesh","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105368_bib46","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1093\/nar\/gkz169","article-title":"Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2","volume":"47","author":"Zhou","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"41","key":"10.1016\/j.ebiom.2024.105368_bib47","doi-asserted-by":"crossref","first-page":"25269","DOI":"10.1074\/jbc.271.41.25269","article-title":"Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family","volume":"271","author":"Cairns","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ebiom.2024.105368_bib48","doi-asserted-by":"crossref","DOI":"10.2142\/biophysico.bppb-v19.0021","article-title":"Diverse reactions catalyzed by cytochrome P450 and biosynthesis of steroid hormone","volume":"19","author":"Fujiyama","year":"2022","journal-title":"Biophys Physicobiol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105368_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab187","article-title":"Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment","volume":"22","author":"Luo","year":"2021","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jps.22255","article-title":"Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection","volume":"100","author":"Kawakami","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105368_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1016249728664","article-title":"A\u00a0novel high-through-put assay for screening of pro-apoptotic drugs","volume":"20","author":"Hagg","year":"2002","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105368_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1087057104265040","article-title":"The use of 3-D cultures for high-throughput screening: the multicellular spheroid model","volume":"9","author":"Kunz-Schughart","year":"2004","journal-title":"J\u00a0Biomol Screen"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105368_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/clpt.1992.2","article-title":"Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population","volume":"51","author":"Dahl","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2024.105368_bib55","series-title":"Medical genetics summaries","author":"Pratt","year":"2012"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105368_bib56","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ebiom.2024.105368_bib57","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2147\/DDDT.S239458","article-title":"Metabolic stability assessment of new PARP inhibitor talazoparib using validated LC-MS\/MS methodology: in silico metabolic vulnerability and toxicity studies","volume":"14","author":"Attwa","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105368_bib58","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105368_bib59","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424004043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:37:02Z","timestamp":1778873822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424004043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":60,"alternative-id":["S2352396424004043"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105368","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105368"}}